← Back to Search

Other

LY3437943 (Control) for Kidney Failure

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 31 days postdose
Awards & highlights

Study Summary

This trial tests how much medicine reaches the bloodstream in people with kidney issues vs. healthy people, taking up to 5 weeks.

Eligible Conditions
  • Kidney Failure
  • Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 31 days postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 31 days postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK: Maximum observed concentration (Cmax) of LY3437943
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943

Side effects data

From 2022 Phase 2 trial • 281 Patients • NCT04867785
20%
Decreased appetite
20%
Nausea
15%
Diarrhoea
11%
Constipation
11%
Vomiting
11%
Upper respiratory tract infection
11%
Urinary tract infection
7%
Fatigue
7%
Dyspepsia
4%
Anaemia
4%
Covid-19
4%
Lipase increased
4%
Dizziness
4%
Weight decreased
2%
Cellulitis
2%
Diabetic ketoacidosis
2%
Abdominal pain
2%
Eructation
2%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
12 mg LY3437943 (2 mg)
8 mg LY3437943 (2 mg)
Placebo
1.5 Milligram (mg) Dulaglutide
0.5 mg LY3437943
4 mg LY3437943 (2 mg)
4 mg LY3437943 (4 mg)
8 mg LY3437943 (4 mg)

Trial Design

3Treatment groups
Experimental Treatment
Group I: LY3437943 (Severe Renal Impairment)Experimental Treatment1 Intervention
LY3437943 administered SC to participants with severe renal impairment
Group II: LY3437943 (End-Stage Renal Disease)Experimental Treatment1 Intervention
LY3437943 administered SC to participants with end-stage renal disease
Group III: LY3437943 (Control)Experimental Treatment1 Intervention
LY3437943 administered subcutaneous (SC) to participants with normal renal function
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3437943
2022
Completed Phase 2
~900

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,603 Previous Clinical Trials
3,199,601 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,336 Previous Clinical Trials
403,776 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are more participants being added to this medical experiment?

"According to clinicaltrials.gov, this medical trial does not require new participants at present. Initially posted on November 4th 2022 and last updated on the 3rd of that month, unfortunately it is inactive for now; however, there are 997 other trials actively recruiting patients as we speak."

Answered by AI

Am I eligible to join this clinical experiment?

"This clinical trial is recruiting 20 participants aged between 18 and 85 who are suffering from kidney failure. To be eligible for enrolment, potential candidates must meet the following criteria: healthy male/female as evidenced by physical examination; normal renal function reflected in an eGFR of 90mL/min or higher; BMI ranging from 19.0-40.0kg/m2; males using contraception and females of childbearing age adhering to contraceptive methods (women not of childbearing age can still participate); acceptable BP and pulse rate according to investigator's judgement; Type 2 diabetic patients with HbA1c levels between 5.0"

Answered by AI

Has the FDA sanctioned LY3437943 (Severe Renal Impairment) for public consumption?

"Based on the current available information, LY3437943 (Severe Renal Impairment) is deemed to be safe enough for a Phase 1 trial and therefore receives a score of 1."

Answered by AI

Is this trial open to participants of all ages, including minors?

"This clinical trial requires that participants are between 18 and 85 years of age. For individuals younger than the former or older than the latter, there are 56 trials specifically for minors and 524 study opportunities available to senior citizens respectively."

Answered by AI

Who else is applying?

What state do they live in?
Minnesota
Florida
What site did they apply to?
Nucleus Networks
Orlando Clinical Research Center
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

~12 spots leftby Mar 2025